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A PRDX1 mutant allele causes a MMACHC
secondary epimutation in cblC patients
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To date, epimutations reported in man have been somatic and erased in germlines. Here, we
identify a cause of the autosomal recessive cblC class of inborn errors of vitamin B12 meta-
bolism that we name “epi-cblC”. The subjects are compound heterozygotes for a genetic
mutation and for a promoter epimutation, detected in blood, ﬁbroblasts, and sperm, at the
MMACHC locus; 5-azacytidine restores the expression of MMACHC in ﬁbroblasts. MMACHC
is ﬂanked by CCDC163P and PRDX1, which are in the opposite orientation. The epimutation is
present in three generations and results from PRDX1 mutations that force antisense tran-
scription ofMMACHC thereby possibly generating a H3K36me3 mark. The silencing of PRDX1
transcription leads to partial hypomethylation of the epiallele and restores the expression of
MMACHC. This example of epi-cblC demonstrates the need to search for compound
epigenetic-genetic heterozygosity in patients with typical disease manifestation and genetic
heterozygosity in disease-causing genes located in other gene trios.
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Epigenetic diseases are caused by stable alterations of DNAmethylation, posttranslational histone modiﬁcation, and/orproduction of non-coding RNA. These phenotypic traits
may be transmitted from parents to offspring. They are termed
epimutations when they are directly involved in the underlying
molecular mechanisms of the disease. Epimutations can be
separated into two types, primary and secondary, the latter
occurring secondary to a DNA mutation in a cis- or trans-acting
factor1, 2. In most cases, epimutations are somatic and are likely
to exist as mosaics with tissue-speciﬁc effects2–4. To our knowl-
edge, to date there is no evidence of epimutations maintained in
germlines in any of these cases2. For example, an epimutation
reported in three generations with a familial cancer syndrome
caused by epigenetic silencing of the MLH1 gene is erased in
spermatozoa, but reinstated in the somatic cells of the next
generation3, 5.
Here, we report cases with a rare inborn error of metabolism
produced by the inheritance of a gene mutation that disrupts the
gene function of a ﬂanking gene through epigenetic mechanisms
in somatic and germ line cells. The cases were classiﬁed as
belonging to the autosomal recessive cblC (cobalamin, Cbl) class
of inborn errors of vitamin B12 metabolism, usually caused by
homozygous or compound heterozygous mutations in the
MMACHC gene6, 7. MMACHC encodes a protein with both
chaperone and enzyme functions, and its inactivation disrupts the
synthesis of two Cbl derivatives, methylcobalamin (MeCbl) and
adenosylcobalamin (AdoCbl), which serve as cofactors for
methionine synthase and methylmalonyl-CoA mutase, respec-
tively6, 7. The cblC disorder presents with both severe neurologic
and systemic metabolic abnormalities6. Here, we report a new
cause of the cblC class of inborn errors of vitamin B12 metabolism
that we name “epi-cblC”. The epi-cblC cases are compound het-
erozygous for a genetic mutation and a secondary epimutation at
the MMACHC locus. The secondary epimutation was triggered
by variants in the neighboring 3ʹ antisense gene PRDX1 that
produces an aberrant antisense transcript by skipping the poly-
adenylation site.
Results
Identiﬁcation of a new cause of cblC named epi-cblC. We
initially identiﬁed the MMACHC secondary epimutation in two
infant females with paternal transmission, case CHU-12122 (died
at 1 month of age, Caucasian ancestry) and case WG-3838 (died
at 2 months of age, Japanese and Korean ancestry) and in a 59-
year-old male (case WG-4152, Caucasian ancestry). The cblC
diagnosis was based on metabolic and ﬁbroblast complementa-
tion analyses. Patient clinical and metabolic data are detailed in
the Methods section.
Sanger sequencing of MMACHC in DNA of CHU-12122
revealed a single heterozygous c.270_271insA, p.Arg91LysfsX14
mutation, which was also identiﬁed in her unaffected mother and
maternal grandfather (Fig. 1a). The maternal grandfather and the
father had serum concentrations of homocysteine of 33.6 and
17.0 µmol/L, respectively (reference levels <15 µmol/L). No
sequence variant in MMACHC was identiﬁed in the father and
no additional gene mutations were identiﬁed in the patient and
her relatives using the TruSight NGS Illumina panel of the genes
involved in metabolic diseases. We performed methylation
analysis of the MMACHC gene by PCR ampliﬁcation and
cloning, followed by Sanger sequencing of bisulﬁte-treated
DNA. This revealed a heterozygous epimutation consisting
of 32 hypermethylated CpG sites in a CpG island encompassing
the promoter and ﬁrst exon of MMACHC
(Chr1:45,965,587–45,966,049) (Fig. 1b, c). The epimutation was
observed in ﬁbroblast DNA from the patient, blood and sperm
DNA from her father, and blood DNA from her paternal
grandfather. We detected a c.-302G allele of the rs3748643
bearing the epimutation and a c.-302T allele bearing the non-
methylated allele. The epimutation and c.-302G allele of
rs3748643 were absent in the DNA from the mother and
maternal grandmother (Fig. 1a, c). The MMACHC allele bearing
the c.270_271insA mutation was the only one detected by RT-
PCR analysis of patient ﬁbroblast transcripts. Treating the
ﬁbroblasts with 5-azacytidine (5-AZA), an inhibitor of DNA
methyltransferases (DNMTs), produced bi-allelic MMACHC
expression (Fig. 1d). Taken together, these results showed an
epimutation causing promoter hypermethylation and MMACHC
silencing in the paternally transmitted allele and a c.270_271insA
mutation in the allele inherited from the mother. The epimuta-
tion was present in three generations; it was transmitted to CHU-
12122 by her father, and to her father by her grandfather and was
present in the sperm of CHU-12122’s father.
Sanger sequencing of MMACHC in blood DNA of WG-3838
revealed the presence of a previously reported heterozygous
c.81G>A splice variant in the patient, her mother, and a deceased
brother (Fig. 2a)8. RT-PCR of ﬁbroblast transcripts found no
detectable MMACHC cDNA. No paternal MMACHC mutation
was identiﬁed. Sequencing of bisulﬁte-converted DNA identiﬁed
the same mono-allelic epimutation as that identiﬁed in CHU-
12122 in blood DNA samples from her and her father and in
sperm from her father; the patient was compound heterozygous
for the c.81G>A mutation and the MMACHC epimutation
(Fig. 2b). In contrast to CHU-12122, the c.-302T allele of the
rs3748643 c.-302 G>T polymorphism was detected with the
epimutation and the c.-302G allele tagged the non-methylated
allele. Taken together, these data showed a presentation similar to
case CHU-12122. The epimutation silenced MMACHC gene
expression in the ﬁbroblasts.
Sequencing of the MMACHC gene in blood DNA of WG-4152
identiﬁed a previously described heterozygous c.158T>C (p.
Leu53Pro) mutation9. Sequencing of bisulﬁte-converted DNA
identiﬁed the same mono-allelic epimutation found in CHU-
12122 and WG-3838. The patient was compound heterozygous
for the c.158T>C mutation and the MMACHC epimutation. The
c.-302G allele of rs3748643 was detected in the allele bearing the
epimutation and the c.-302T allele in the non-methylated allele.
Conﬁrmation of the epimutation by epigenome-wide analysis.
We performed an epigenome-wide study of DNA from the 3 epi-
cblC cases and their relatives using the Inﬁnium HumanMethy-
lation450 BeadChip array (HM450K)10. The methylation varia-
tion positions (MVPs) of the three cases were compared to those
observed in 690 DNA samples from a Caucasian population from
the Asthma BRIDGE consortium (USA)11, 350 DNA samples
from a Caucasian population recruited in the South of France (the
MARTHA cohort)12, and one typical cblC (CHU-09011) sample
with compound heterozygosity for the same mutation as CHU-
12122 in exon 2 (c.270_271insA, p.Arg91 > LysfsX14) and an
exon 4 mutation (c.616C>T, p.Arg206Trp). The HM450K array
included eight probes covering the CpG sites of the epimutation
(Fig. 1b). HM450K methylome proﬁling in the three epi-cblC
cases and their relatives conﬁrmed the results obtained by Sanger
sequencing of bisulﬁte-treated DNA (Fig. 2c, Fig. 2d). The epi-
mutation was also conﬁrmed in sperm from the fathers of the
CHU-12122 and WG-3838 cases. The CpG hypomethylation in
sperm DNA from a control population from Utah13 was similar
to that observed in the genomic DNA of the control subjects
(Fig. 2e). We observed only one subject in the control population
with the same hypermethylation of the MMACHC sites as was
reported in the epi-cblC cases and their relatives. The allele
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Fig. 1 The CHU-12122 epi-cblC case is compound heterozygous for a coding mutation and an epimutation of MMACHC detected in three generations. a
Pedigree of the family of case CHU-12122; red bar, mutation (heterozygous c.270_271insA, p.Arg91LysfsTer14) found in the proband, her mother, and her
maternal grandfather; green circle, epimutation encompassing the MMACHC promotor/exon 1 found in the proband. b Map of the MMACHC gene and
expanded view of the MMACHC CpG island. CpG sites are numbered according to their position upstream and downstream of ATG. Asterisks indicate the
CpG sites of the CpG island which were probed in the HM450K array. c Epigrams ofMMACHCmethylation analyzed by PCR ampliﬁcation/cloning/Sanger
sequencing of bisulﬁte-treated DNA. Epimutations were detected in the proband, her father, and her paternal grandfather. d RT-PCR of ﬁbroblasts from
case CHU-12122 before and after the 3-day treatment with 10 µM 5-azacytidine (5-AZA). Silencing of the wild-type allele (mono-allelic expression in upper
panel, red arrow) was reversed after treatment (bi-allelic expression after treatment, lower panel, red arrow)
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frequency of the epimutation was therefore not higher than 5 × 10
−4 in the control population. We also conﬁrmed the absence of
the MMACHC epimutation in the CHU-09011 cblC case.
To compare the epigenome-wide changes between the three
cases and their relatives with those from the control population,
we plotted the difference between the beta methylation
coefﬁcients of the MVPs in cases and relatives and those reported
in the MARTHA control population for each CpG site probed in
the HM450 array. The ‘epi-Manhattan’ plot generated by this
analysis showed that the MMACHC epimutation was the single
change greater than 0.3 that reached a high level of statistical
signiﬁcance (Fig. 3a). In the control population, the CpG island
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Fig. 2 The MMACHC epimutation is found in a second case and is present in sperm of both cases. a Pedigree of the family of case WG3838; red bar,
mutation (heterozygous c.81G>A splice variant) found in the proband, her mother, and a deceased brother; green circle, epimutation encompassing the
MMACHC promotor/exon 1 found in the proband and her mother. No material from the deceased brother was available to study the presence of the
epimutation. b MMACHC methylation epigrams after PCR ampliﬁcation/cloning/Sanger sequencing of the bisulphite-treated DNA from blood obtained
from WG-3838, her father CHD867, WG-4152, and from sperm obtained from CHD867. The epimutation was identiﬁed in all samples. c HM450K array
methylome proﬁling of the epimutation in the CHU-12122 case and her relatives. The data conﬁrmed the results obtained in Fig. 1c. d Methylome proﬁling
conﬁrms the epimutation in blood DNA from case WG-3838, her father CDH-867, and case WG-4152; the dotted line corresponds to a β value threshold
of 0.2, below which the CpG probe was considered fully unmethylated. eMethylome proﬁling of sperm DNA from the father of case CHU-12122, the father
of case WG-3838, and a control population of Utah. The data conﬁrm the epimutation’s presence in the sperm; the dotted line corresponds to a β value
threshold of 0.2, below which the CpG probe was considered fully unmethylated. The absence of sperm DNA contamination by DNA from somatic cells
was proven by methylation analysis of SNRPN imprinted gene (see Supplementary Fig. 1)
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that encompassed the promoter and the ﬁrst exon of MMACHC
was hypomethylated14 and surrounded by hypermethylated CpG
sites (Fig. 3b, c). This corresponded to an ‘epi-haplotype block’
composed of the eight CpG sites probed by the HM450K array
(Fig. 3b, c). Expression of MMACHC is regulated by a
transcription regulatory complex of proteins that involves
HCFC1, THAP11, and ZNF14315. Analysis of the HM450K
methylome failed to ﬁnd any aberrant hypermethylation related
to HCFC1-ZNF143-THAP11 in our epi-cblC cases.
We performed ChIP-Seq analyses on the chromatin of case and
control ﬁbroblasts to further characterize the epigenetic changes
at MMACHC and neighboring genes (Fig. 4a). We observed a
signiﬁcant accumulation of trimethylated lysine 36 on histone H3
(H3K36me3) in the MMACHC promoter region and the
proximal part of the 5′ adjacent CCDC163P gene only in patients
harboring the epimutation (Fig. 4a). In contrast, all control and
patient samples show the absence of the H3K36me3 mark in the
promoter region of PRDX1, the gene 3′ to MMACHC (which was
associated with the absence of DNA hypermethylation).
The MMACHC epimutation occurs secondary to a PRDX1
mutation. We performed whole-genome sequencing (WGS) of
DNA from cases CHU-12122 and WG-3838 and their relatives to
determine whether the promoter hypermethylation of MMACHC
was a secondary epimutation that resulted from a genetically
heritable variant1, 2, 16. The only sequence variant that segregated
with the phenotype across all samples was in PRDX1 (Fig. 4b and
Fig. 5a). PRDX1 is located adjacent to MMACHC and on the
opposite strand. We found a c.515-1G>T mutation of PRDX1 in
cases CHU-12122 and WG-4152 and a c.515-2A>T mutation of
the same gene in WG-3838 (Fig. 4b). These PRDX1 mutations
were also found in the relatives who carried the secondary epi-
mutation, i.e., the father and paternal grandfather of CHU-12122
and the father of WG-3838 (Fig. 5a). The PRDX1 variants and the
polymorphism rs3748643 associated with the secondary epimu-
tation were present in the same allele as evidenced by DNA
sequencing and transmission in the heterozygous relatives (Fig. 1c
and Fig. 2b).
Presence of the secondary epimutation in additional cases. We
replicated our results in ﬁve cases from two other centers. We
found the secondary epimutation and the c.515-1G>T PRDX1
mutation in all ﬁve cases, and conﬁrmed the maternal trans-
mission of the PRDX1 mutation with the secondary epimutation
in one case (Supplementary Table 1). The c.515-1G>T variant
was present in seven individuals of European ancestry out of
66,000 individuals reported in the Exome Aggregation Con-
sortium (ExAC) database (estimated frequency in the general
population 1.052 × 10−4).
The epimutation results from PRDX1 antisense transcription.
MMACHC belongs to a trio of reverse (R1)–forward (F2)–reverse
(R3) genes with dual partial overlaps ofMMACHC by CCDC163P
and PRDX1 at its 5′ and 3′ ends, respectively. The two mutations
in PRDX1 affect the canonical splice acceptor site of intron 5, 1
and 2 bp apart, respectively. They are predicted to disrupt normal
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splicing and to produce skipping of exon 6 and the polyA tran-
scription termination signal of PRDX1. We conﬁrmed this pre-
diction by single-strand RNA-Seq and RT-PCR analyses of case
ﬁbroblasts, and found that the loss of transcription termination of
PRDX1 produced an aberrant extension of antisense transcription
through the MMACHC and CCDC163P genes. The level of
antisense transcripts was high in case ﬁbroblasts and undetectable
in control ﬁbroblasts. The activation of cryptic acceptor sites and
the resulting skipping of exons and introns of MMACHC gen-
erated several transcripts identiﬁed in both RNA-Seq and RT-
PCR. Among them, we identiﬁed a predominant 1.0 kb transcript
that encompassed the exons 4 and 5 of PRDX1, the CpG island
and the bidirectional promoter, and the ﬁrst exon of CCDC163P
(Fig. 5b, Fig. 6a, b, c). This transcript resulted from the activation
of a cryptic antisense splicing site located in the middle of
MMACHC exon 1 (Fig. 6d, e).
We further demonstrated that the PRDX1 mutation produced
the silencing ofMMACHC expression through the methylation of
its promoter. To address this issue, we silenced the expression of
PRDX1 with siRNA transfection in WG-3838 ﬁbroblasts and the
cell line MeWo-LC1. We used WG-3838 ﬁbroblasts because of
the complete absence of detectable sense transcription of
MMACHC exons. We showed previously that the MeWo-LC1
melanoma-derived cell line had a cblC phenotype and no
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Fig. 4 The MMACHC epimutation is associated with a H3K36me3 chromatin mark in the promoter and a mutation in the PRDX1 adjacent gene. a Results of
ChIP-Seq analyses at the genomic region encompassing the promoters of MMACHC/CCDC163P and PRDX1. Genomic panels show normalized coverage for
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transcription of MMACHC 17. We found recently that this cell
line had the same antisense transcription of PRDX1 found in
patient ﬁbroblasts. We observed that the silencing of PRDX1
restored the expression of MMACHC in both cell lines and that it
produced 10–15% hypomethylation of the allele initially fully
methylated in the clones generated from bisulﬁte-treated DNA.
No effect was observed in control ﬁbroblasts transfected with the
PRDX1 siRNA and in WG-3838 ﬁbroblasts and MeWo-LC1 cells
transfected with a control siRNA (Fig. 6f, g).
Discussion
Our epi-cblC cases represent a cause of the autosomal recessive
cblC disorder, resulting from a secondary epimutation in the
bidirectional promoter of MMACHC on one allele and a coding
mutation on the other. The secondary epimutation is caused by
an inherited mutation of the adjacent PRDX1 gene. It is directly
involved in the mechanism of the disease through the forced
antisense transcription of the adjacent mutated PRDX1 and is
present in three generations. Previous reports have described
DNA methylation at genes that mimics recessive mutations by
creating a transcriptional haploinsufﬁciency with tissue-speciﬁc
epigenetic silencing18. In contrast, the secondary epimutation
seen in our cases is present in the DNA from blood cells, ﬁbro-
blasts, and sperm. The high expression of PRDX1 in spermatic
cells may explain the presence of the epimutation in sperm, in
contrast to the spermatozoa erasure previously observed in
families with epigenetic silencing of the MLH1 gene5, 14.
The secondary epimutation of our epi-cblC cases is located in a
trio of genes (reverse CCDC163P–forward MMACHC–reverse
PRDX1) (Fig. 6d, e), in a bidirectional promoter in the head-to-
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head sense–antisense gene pair (SAGP) constituted by
CCDC163P and MMACHC. The forced antisense transcription of
MMACHC resulted from the skipping of the last exon of PRDX1.
This skipping was the causative defect that produced the epi-
mutation since the silencing of PRDX1 decreased the methylation
of exon 1 of MMACHC and the promoter, and restored the
transcription of MMACHC, in WG-3838 and MeWo-LC1 cells.
However, the silencing of PRDX1 produced only 10–15% hypo-
methylation of the allele initially fully methylated, suggesting a
limited reversibility of the epimutation (Fig. 6g). Antisense
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Fig. 6 The PRDX1 mutation causes aberrant antisense transcription through the MMACHC and CCDC163P genes. a qRT-PCR analyses of antisense
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transcription could lead to RNA polymerase collision and the
formation of triplexes in the bidirectional promoter19. The for-
mation of triplexes can generate CpG methylation, as shown for
PARTICLE and MAT2A SAGP in cells exposed to radiation20.
Recent data also strongly support a role of antisense transcription
of SAGP in the generation of H3K36me3 marks, in the devel-
opmental mechanisms of yeast, and in the Igf2r promoter of
mouse embryonic stem cells (ESC)21. The H3K36me3 mark could
play a major role in the de novo methylation of the CpG island. It
may reﬂect the rate of antisense transcription as it is deposited by
the histone−lysine N-methyltransferase SETD2 at active genes,
where it binds to the active form of RNA polymerase II22. The de
novo methylation of CpG islands is preferentially targeted to
genomic regions with elevated H3K36me3 levels through the
recruitment of DNMT3B1 in mouse stem cells23.
To our knowledge, the epi-cblC entity is the ﬁrst example of
human epigenetic disease documented by the presence of a sec-
ondary epimutation in three generations and its presence in
sperm of the probands’ fathers. Gene silencing by methylation
through a gene disruption that caused antisense transcription
across the CpG island of the promoter was previously reported
for HBA2 (alpha-thalassemia) and MLH1 (familial cancer syn-
drome)24–26. In contrast to our data, epigenetic silencing of HBA2
and MLH1 caused by antisense transcription is not maintained in
sperm24–26. In another example of familial cancer, the epigenetic
somatic inactivation of the MSH2 allele resulted from the
extension of the sense transcription of the upstream EPCAM
(formerly TACSTD1) gene produced by microdeletions in cis27.
The presence of the MMACHC secondary epimutation in DNA
from sperm, ﬁbroblasts, and blood may be explained by the
ubiquitously high expression of PRDX1 in germ cells, stem cells,
and somatic cells. The high expression of PRDX1 in germ cells
may explain why the secondary epimutation escaped erasure in
spermatozoa, in contrast to previous reports of other diseases5, 14.
The high expression of PRDX1 could also maintain this epimu-
tation during early embryonic development. The transcription of
PRDX1 has been studied in bovine embryos from the two-cell to
the blastocyst stages28. PRDX1 transcripts were detected
throughout development, including in oocytes before and after
maturation and in 2c, 5–8c, 9–16c embryos, morulae, and blas-
tocysts. PRDX1 was also ubiquitously expressed in E7–E10 mouse
embryos (http://www.informatics.jax.org; http://dbtmee.hgc.jp/)
and adult humans (http://www.proteinatlas.org). The methylation
of the promoter in sperm is also consistent with previous results
in a mouse model, in which genes with high H3K36me3 levels
showed elevated gene-body DNA methylation in sorted germ
cells of pooled E13.5 testes29.
The cases of epi-CblC provide the ﬁrst example of a rare disease
produced by compound epigenetic/genetic heterozygosity in a
reverse1 (R1)–forward2 (F2)–reverse3 (R3) trio of genes (Fig. 6d,
e). This suggests consideration of this mechanism in cases of
recessive diseases bearing a single heterozygous variant in the
causal gene in the presence of typical disease manifestations. The
number of R1–F2–R3 trios of genes with a conﬁguration similar
to the CCDC163P–MMACHC–PRDX1 trio is limited in the
human genome30. We have listed examples of such trios with a
recessive transmission of inherited diseases produced by F2 gene
mutations (Supplementary Table 2). In most of them, the CpG
island is hypomethylated and the RNA-Seq analysis of control
ﬁbroblasts shows the absence of aberrant transcription of the
adjacent genes31, 32. Our data suggest that the presence of an
epimutation in patients with a single heterozygous mutation and
a severe phenotype for any of these diseases should be system-
atically investigated.
In contrast to coding mutations, pharmacological inhibitors of
DNMTs such as 5-AZA can reverse epigenetic changes.
Consistently, treatment of ﬁbroblasts from one of our epi-cblC
cases with 5-AZA restored bi-allelic MMACHC expression with
detection of the wild-type allele (Fig. 2a). This suggests that
further evaluation of the use of this compound in the treatment of
potentially fatal, severe decompensation in these ‘epi-diseases’, as
observed in our two pediatric cases, is warranted.
In conclusion, we report cases of a rare metabolic disease
caused by compound heterozygosity of a secondary epimutation
detected in somatic cells and sperm in one allele and a genetic
mutation in the other. These cases represent an entity that we
named “epi-cblC”. This research reveals perspectives on the
diagnosis and treatment of inherited metabolic diseases in general
and “epi-cblC” patients in particular. It suggests to search for
epimutations in rare diseases with typical severe presentation
despite heterozygous gene mutation.
Methods
Patients. Informed written, signed consent for performing the analyses was
obtained from all subjects and from the parents, when appropriate. We followed
the rules of the French National Reference Center of Inborn Metabolism Diseases
of Nancy that were reviewed and approved by The Haute Autorité de Santé (HAS,
Sain Denis, France, https://www.has-sante.fr/) for the study of the patients and
their relatives. Case 1 (CHU-12122) was the ﬁrst child of an unrelated Caucasian
couple, with a healthy paternal half-brother and a healthy paternal half-sister. A
history of Sudden Infant Death Syndrome was reported for the father’s sister. The
mother had three episodes of spontaneous abortion of unknown origin. The
proband was born at term with a low birth weight of 2450 g. After 1 month of
breastfeeding, she had marked mucocutaneous pallor, tachycardia, and axial
hypotonia. Further investigations during hospitalization showed megaloblastic
anemia with 3.5 g/dL hemoglobin, discrete concentric myocardial hypertrophy,
pulmonary hypertension, and hepatomegaly. Serum vitamin B12 and folate levels
were within the reference ranges. Impaired activities of methionine synthase and
methylmalonyl-CoA mutase were reﬂected by decreased methionine at 5 μmol/L
(24–38) and increased homocysteine and methylmalonic acid at 174 μmol/L
(reference range <0.15 µmol/L) and 325 μmol/L (reference range <0.35 µmol/L),
respectively. She was diagnosed with cblC by ﬁbroblast complementation analysis.
The patient died at 1 month of age after multiple organ failure with hypotension,
desaturation, and severe bradycardia.
Patient WG-3838 was born after an uneventful full-term pregnancy and
weighed 3400 g. Her older brother died at 1 month of age from cardiac arrest, and a
cardiomyopathy was noted upon autopsy. At week 5, the patient was taken to the
emergency room. Serum vitamin B12 was within the reference range, serum
methionine was low, and homocysteine and MMA were increased to 110 and 20
µmol/L, respectively. The patient was hypertensive and developed tachycardia. She
had a sudden cardiac arrest and developed acute renal failure. She had a second
cardiac arrest and died at age 2 months. She was diagnosed as a cblC case by
ﬁbroblast complementation analysis.
Patient WG-4152, a 59-year-old male, had a history of squamous cell carcinoma
of the left palatine tonsil. Four months after surgery, he developed an oral thrush
and vomiting and underwent several tests including metabolic analyses. All results
were within the reference range, except for MMA (9.0 µmol/L) and homocysteine
(99 µmol/L). He was diagnosed as a cblC case by ﬁbroblast complementation
analysis.
Control populations. The Asthma BioRepository for Integrative Genomic
Exploration consortium (Asthma BRIDGE consortium, USA) is an open-access
collection of cDNA and DNA from more than 1450 well-characterized subjects
participating in ongoing genetic studies of asthma and an accompanying database
of phenotype, genome-wide SNP genotype, gene expression, and methylation
data11. The Caucasian population of the MARTHA (MARseille THrombosis
Association) cohort was recruited in the Thrombophilia Centre of La Timone
University Hospital (Marseille, France) between January 1994 and October 200512.
The MH450K proﬁling data of the sperm DNA from the control population in
Utah are publicly available at the Gene Expression Omnibus under #GSE64096,
Utah cohort13.
Studies in skin ﬁbroblasts. We measured the cellular incorporation of the label
from 1-[14C]propionate and 5-[14C]methylTHF into cellular macromolecules that
precipitated in 5% trichloroacetic acid at 5 °C to evaluate the metabolic functions of
methylmalonylCoA mutase (MUT) and methionine synthase (MS), respectively. If
incorporation was signiﬁcantly reduced, complementation analysis was performed.
Patient cells were fused with ﬁbroblasts from patients with different inborn errors
of cobalamin metabolism, and the incorporation of labeled [14C]propionate and 5-
[14C]methylTHF was measured in parallel in fused and unfused cells. Decreased
incorporation was complemented by ﬁbroblasts from all classes of inborn errors
except for the class to which the patient belonged. These tests were used to assign
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patients to known complementation classes6. Treatment with 5-aza-2′-deox-
ycytidine (5-aza-dC) was performed in ﬁbroblasts from case CHU-12122. Fibro-
blasts were seeded at 3 × 105 cells/100-mm dish 24 h prior to treatment in DMEM
supplemented with 10% fetal calf serum at 37 °C and 5% CO2. Cells were exposed
for 72 h to 10 µM 5-aza-dC (Sigma-Aldrich Chimie S.a.r.l, St. Quentin, France).
The culture media was replaced every 24 h with fresh media containing 5-aza-dC.
At day 3, TRIzol® reagent (Thermo Scientiﬁc™, Fontenay-sous-Bois, France) was
used to extract the total RNA from the cultured ﬁbroblasts. RT-PCR was per-
formed with RNA from treated and non-treated cells, using the primers listed in
the Supplementary Table 3. First-strand cDNA was synthesized from 2 µg of total
RNA using the SuperScript First-Strand Synthesis System (Invitrogen). PCR
ampliﬁcation of the whole open-reading frame of MMACHC was performed with
Phusion High-Fidelity DNA Polymerase (Thermo Scientiﬁc, Fontenay-sous-Bois,
France) under standard conditions. The primers used for MMACHC_cDNA
synthesis were: forward, 5′-CAGCAAGCTCAGCGTGTAAC-3′, reverse 5′CCAC-
CATAAATCAGGGTCCA-3′. The RT-PCR amplicon was sequenced by direct
sequencing using the BigDye Terminator v.3.1 kit (Thermo Scientiﬁc™, Fontenay-
sous-Bois, France) and the same primers.
For RNA-Seq and RT-qPCR study of aberrant transcription, RNA depleted of
rRNA transcripts was extracted from case and control ﬁbroblasts using
RiboMinus™ (Thermo Scientiﬁc, Villebon, France). cDNA libraries were prepared
using the TruSeqTM RNA Sample Preparation Kit (Illumina, San Diego, CA,
USA). RNA sequencing was performed using the Illumina Hi-scan sequencer.
Reads were classiﬁed according to known 5′ and 3′ boundaries of annotated genes.
For RT-PCR study of aberrant transcription, ﬁrst-strand cDNA was synthesized
from 2 µg of total RNA using random primers with SuperScript II reverse
transcriptase (Invitrogen, Mantes la Jolie, France) according to the manufacturer’s
protocol. PCR reactions were performed with Phusion High-Fidelity DNA
Polymerase (Thermo Scientiﬁc™, Fontenay-sous-Bois, France). Primers for the
synthesis of PRDX1-CDC1623P 1007 bp transcript were PRDX1-S forward 5′-
CATTCCTTTGGTATCAGACCCG-3′ and CCDC163P-AS reverse 5′-
AGCGTTGAGAAGCACATCCA-3′. The expression of the aberrant transcript was
quantiﬁed by real-time PCR using PrimeScript™ RT Master Mix and SYBR
Premix Ex Taq (Takara, Ozyme St Quentin en Yvelines, France) on a StepOne Plus
machine (Applied Biosystems) with Pol II as an internal control.
DNA extraction. Genomic DNA was extracted from conﬂuent cultures of ﬁbro-
blasts using the QIAmp kit (Qiagen, Courtaboeuf, France). Genomic DNA from
EDTA-treated peripheral blood samples was isolated using the Nucleon BACC3
Kit. (GE Healthcare, Aulnay-sous-Bois, France). Sperm DNA was extracted from
spermatozoa isolated by a swim-up protocol to discard contaminating somatic
cells. Microscope examination conﬁrmed the purity of spermatozoa and absence of
somatic cells. Furthermore, the absence of somatic cells was proven by methylation
analysis of SNRPN, a robustly imprinted gene. All SNRPN reads are unmethylated
in the DNA extracted from our sperm preparations. The sperm sample was heated
at 56 °C for 2 h with frequent shaking in the lysis buffer, and DNA was extracted
using the DNeasy Blood and Tissue Kit (Qiagen, Courtaboeuf, France).
Determination of DNA methylation. The methylation status of the CpG island in
the 5′-region of the MMACHC gene (RefSeq: Chr1:45,965,587 to Chr1:45,966,049)
was determined by bisulﬁte conversion, cloning, and sequencing of individual
clones. Six-hundred nanograms of genomic DNA was converted by bisulﬁte using
the EZ DNA Methylation-Gold kit (Zymo Research, Proteigene, Saint-Marcel,
France). The bisulﬁte-treated DNA was ampliﬁed by PCR (primers: forward 5′-
TTAAATTTGTGTTAGTGATAATTGT-3′, reverse 5′-AACTAACC-
TAAAAAAAATAAACCTC-3′) using ZymoTaq DNA Polymerase (Zymo
Research). The amplicon was inserted into the pCR4-TOPO vector (Invitrogen,
Life Technologies, Courtaboeuf, France), and individual clones were sequenced in
both directions using universal M13 primers and the BigDye Terminator v.3.1
Sequencing Kit (Applied Biosystems, Courtaboeuf, France). Only DNA strands that
were >95% converted were used for analysis. Methylome analysis for genome-wide
proﬁling of bisulﬁte-converted DNA was determined using the Inﬁnium
HumanMethylation450 BeadChip array (Illumina, Paris, France), according to the
manufacturer’s instructions. Probe annotation information including sequence and
chromosome location for the Inﬁnium HumanMethylation450 BeadChip array was
retrieved from the HumanMethylation450 v1.2 manifest ﬁle.
Gene sequencing. WGS was performed using our standard protocols at the McGill
University and Génome Québec Innovation Center33. All samples were sequenced
using the HiSeq X Ten Illumina System sequencer with paired-end 150-bp read
length and the mean average of 35–37X. Bioinformatics analysis was performed as
previously described34. Brieﬂy, the Burrows-Wheeler Aligner (BWA-MEM, version
0.7.7) was used to map all reads to UCSC hg19. PCR duplicates were removed from
alignments using Picard version 1.96 (http://picard.sourceforge.net). Indels were
realigned using the Genome Analysis Toolkit (GATK). SNVs and short indels were
called using GATK haplotype caller (version 3.4–46). All variants were annotated
with ANNOVAR and in-house scripts, and most likely protein damage variants
(nonsense, splice site, frameshift indel, and missense) were considered for further
analysis. The variants were also annotated for the allele frequency in public
databases such as ExAC (http://exac.broadinstitute.org/), the National Heart, Lung,
and Blood Institute (NHLBI) exomes (V.0.0.14, http://evs.gs.washington.edy/EVS/
), the 1000 Genomes Project database, and our in-house database of >2000 exomes.
In order to remove common variants and sequencing artifacts, variants with MAF
>0.001 in any of the aforementioned databases were removed from further
analysis.
Whole-genome ChIP-Seq. ChIP-Seq was performed in patient’s ﬁbroblasts and
control ﬁbroblast lines without inherited metabolic defects in the cobalamin
pathway. MCH23 ﬁbroblasts were obtained from a healthy 3-year-old male, WG-
4301 ﬁbroblasts were from a 3-month-old female, and WG-3679 ﬁbroblasts were
from a 5-year-old female with mut mutation. For crosslinking, cells were directly
ﬁxed with formaldehyde (ﬁnal concentration of 1%) for 10 min with gentle shaking
at room temperature. The ﬁxed cells were then quenched with glycine at a ﬁnal
concentration of 138 mM for 5 min at room temperature. The crosslinked cells
were subsequently washed with 10 mL ice-cold PBS and scraped. The cells were
pelleted by centrifugation at 5000×g for 5 min at 4°C. For cell and nuclear lysis, the
crosslinked cell pellets were resuspended in ice-cold Cell-Lysis buffer (5 mM PIPES
pH 8.5, 85 mM KCl, 1% IGEPAL CA-630, 50 mM NaF, 1 mM PMSF, 1 mM
phenylarsine oxide, 5 mM sodium orthovanadate, 1× Roche complete mini EDTA-
free protease inhibitors) at 500 μL/10 million cells and incubated for 15 min on ice.
The nuclei were pelleted by centrifugation at 5000×g for 10 min at 4°C. Nuclei were
lysed in Nuclear-Lysis buffer (50 mM tris-HCL pH 8.0, 10 mM EDTA, 1% SDS, 50
mM NaF, 1 mM PMSF, 1 mM phenylarsine oxide, 5 mM sodium orthovanadate,
1× Roche complete mini EDTA-free protease inhibitors) at 100 μL/1 million cells
adjusting by 50 μL for every excess of 10 million additional cells. The nuclei were
incubated for 30 min on ice and then transferred to 1.5 mL TPX tubes (Diagenode)
at 100–250 μL aliquots. The lysed nuclei were sonicated with a UCD-300 Diag-
enode Bioruptor on high power at 4°C with repeated cycles. The chromatin size
distribution was evaluated on 2% pre-cast E-gels (Invitrogen). Samples with
chromatin size distribution >500 bp were further sonicated. For chromatin con-
centration and pre-clearing, the material was ﬁrst spun down at 12,000×g for 10
min at 4°C. The resulting pellets were washed with 10 mM tris-HCl pH 8.0 and
pooled with collected supernatant for each sample. The chromatin material was
then concentrated to a desired volume equivalent to 50 μL/1 million cells and
<0.1% SDS using Nanosep 10k omega centrifugal devices (PALL life sciences). The
chromatin was then pre-cleared with 50 μL Protein A Dynabeads for 1 h at 4°C
with rotation. The Immunoprecipitation and reverse crosslinking were performed
with the IP-Star SX-8G (Diagenode) using the Auto-Histone ChIP kit (Diagenode)
according to the manufacturer’s instructions. Input material was prepared by fol-
lowing the reverse crosslinking procedure above, but without immunoprecipita-
tion. The eluted material was collected by placing the samples on a magnetic rack.
DNA was extracted using Qiagen’s MinElute PCR puriﬁcation columns. ChIP-Seq
libraries were prepared using the Kappa Library Preparation Kit Illumina Platforms
(Kappa Biosystems) and Illumina TruSeq adapters (Illumina) according to the
manufacturer’s instructions. DNA clean-up and size selection was performed using
Ampure XP Beads. Samples were then sequenced using the HiSeq 2000 with
selected read length of 50 bp. Sequence reads were aligned as explained for the
WGS bioinformatic analysis. Duplicated reads were removed using PICARD. Peaks
were called using Model-based Analysis of ChIP-Seq MACS2 with input DNA as
control and using the broad peak mode (--broad --broad-cutoff 0.1)35. In order to
generate Wiggle (WIG) and Tiled Data Format (TDF) ﬁles, HOMER (4.7)36 and
igvtools (2.3.67; http://software.broadinstitute.org/software/igv/igvtools) were used.
Tags were normalized to 10 million reads to generate tracks for visualization.
Effect of PRDX1 silencing on MMACHC methylation. The human melanoma cell
line MeWo-LC1 derives from MeWo cells (ATCC® HTB-65™). It was obtained
from Dr. Robert Liteplo (University of Ottawa, Ottawa, Ontario). The human
melanoma cell line MeWo-LC1 variant of MeWo cells, ﬁbroblasts from case WG-
3838, and ﬁbroblasts HDF for control were cultured in DMEM medium supple-
mented with 4.5 g/L glucose, 10% v/v heat-inactivated fetal bovine serum, 1% v/v
pyruvate in a humidiﬁed atmosphere with 5% CO2 at 37 °C. The cell lines were
tested for absence of mycoplasma contamination. The cells were seeded into six-
well plates at a concentration of 0.5 × 105 cells/well the day before transfection; 10
nM of siRNA against PRDX1 gene (GGUCAAUACACCUAAGAAA, GGGCA-
GAAGAAUUUAAGAA, GAUGGUCAGUUUAAAGAUA, and CUU-
CAAAGCCACAGCUGUU) was transfected with Lipofectamine RNAiMAX
transfection reagent (Invitrogen) into MeWo-LC1 for 72 h at 37 °C. Non-silencing
siRNA (AllStars Negative Controls—Qiagen) was used as a negative control. After
a 72-h period of incubation, the cells were collected and used for mRNA and DNA
isolation. Two-hundred nanograms of RNA was reverse-transcribed in a 10-µL
reaction volume using PrimeScript™ RT Master Mix (TAKARA Bio, USA)
according to the manufacturer’s recommendations; 2 µL of cDNA was used for
qPCR with SYBR® Premix Ex Taq™ (Tli RNaseH Plus) (TAKARA Bio, USA) in a
20-µL reaction volume according to the manufacturer’s instructions, with reverse
and forward primers at a concentration of 0.2 µM. Speciﬁc ampliﬁcations were
performed using the following primers: MMACHC forward 5′-
ATCTGGGCCGTGTTAGAGAGA-3′, reverse 5′-CCTCCA-
CATCTTGTCGTTGG-3′; PRDX1 forward 5′-CCACGGAGATCATTGCTTTCA-
3′, reverse 5′-AGGTGTATTGACCCATGCTAGAT-3′. Quantiﬁcation was
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performed using the housekeeping gene RNA polymerase II as an internal standard
with the following primers: forward 5′-CAGACCGGCTATAAGGTGGA-3′,
reverse 5′-GGTAGACCATGGGAGAATGC-3′. Temperature cycling for
MMACHC and PRDX1 was 30 s at 95 °C followed by 40 cycles consisting of 95 °C
for 5 s and 61 °C for 30 s. The PCR program for RNA polymerase II was 30 s at 95 °
C followed by 40 cycles consisting of 95 °C for 5 s and 60 °C for 30 s. Results were
expressed as arbitrary units by calculating the ratio of crossing points of ampliﬁ-
cation curves of MMACHC or PRDX1 and the internal standard by using the δδCt
method. The bisulﬁte-treated DNA from MeWo-LC1 was used for methylation
analysis of the MMACHC gene promoter by PCR ampliﬁcation, cloning, and
Sanger sequencing.
List of sense–antisense trios of genes. We established a list of tail-to-tail SAGPs
using a systematic search through the United Sense-Antisense Gene Pairs Database
and retrieved 385 gene pairs30. Each gene pair was visually inspected (RefSeq Genes
105v2) in order to look for the presence of a ﬂanking gene that meets the two
criteria of sense–antisense trios of genes: (1) antisense with one of the tail-to-tail
SAGPs and (2) sharing a CpG island with the proxy gene (CpG Islands
2009–03–08, UCSC)30, 31. Among the 385 manually inspected gene pairs, 99 had a
triplet gene conﬁguration according to a reverse(R1)–forward(F2)–reverse(R3)
pattern (n = 82) or a forward(F1)–reverse(R2)–forward(F1) pattern (n = 17), with a
CpG island in the promoter of R1/F2 and R2/F1, respectively.
Statistical analyses. The comparison of CpG beta values between the cases and
controls was carried out using a t-test, and multiple testing corrections were per-
formed using the Bonferroni adjustment. To assess the methylome architecture
(epi-haplotype blocks, epi-LD analysis), linkage disequilibrium (LD) pairwise
analysis was performed on all adjacent CpG pairs in a chromosome or within a
haplotype block using a matrix output for both the expectation–maximization
(EM) algorithm and the composite haplotype method (CHM)37. R2 values were
used in the epi-LD plots. All epi-LD analyses were performed after transforming
the CpG beta values to categorical variables according to the ENCODE project10.
Any beta value ⩾0.6 was considered fully methylated (MM). Any beta value ⩽0.2
was considered to correspond to a fully unmethylated DNA. Beta values strictly
greater than 0.2 and strictly less than 0.6 were considered to correspond to a par-
tially methylated DNA (one of the two alleles). To assess the population stratiﬁ-
cation according to their whole methylome proﬁle, numeric principal component
analysis was performed using normalized beta values of each CpG probe across the
Inﬁnium HumanMethylation450 BeadChip array38, 39. The top 10 principal
components (eigenvectors) were calculated with their respective eigenvalue (EV).
Population stratiﬁcation was assessed both in 2-dimensional and 3-dimensional
visualization based on the eigenvalues of the top two and three principal compo-
nents, respectively. All analyses were performed using the SNP & Variation Suite
(SVS) 8.4.2 (Golden Helix, Inc. Bozeman, MT, USA).
Data availability. The RNA-Seq data that support the ﬁndings of this study have
been deposited in the European Genome-phenome Archive (https://www.ebi.ac.uk/
ega/datasets) with the accession code EGAD00001003707. The other data sup-
porting the ﬁndings of this study are available from the corresponding author upon
reasonable request.
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